Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Total Non-Current Liabilities (2016 - 2025)

Avalo Therapeutics' Total Non-Current Liabilities history spans 11 years, with the latest figure at $15.4 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 67.13% year-over-year to $15.4 million; the TTM value through Dec 2025 reached $15.4 million, up 67.13%, while the annual FY2025 figure was $15.4 million, 67.13% up from the prior year.
  • Total Non-Current Liabilities reached $15.4 million in Q4 2025 per AVTX's latest filing, down from $33.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $219.1 million in Q1 2024 to a low of $8.1 million in Q4 2023.
  • Average Total Non-Current Liabilities over 5 years is $46.8 million, with a median of $36.5 million recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: soared 675.46% in 2024, then tumbled 92.87% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $57.1 million in 2021, then dropped by 25.49% to $42.6 million in 2022, then tumbled by 80.88% to $8.1 million in 2023, then increased by 13.28% to $9.2 million in 2024, then soared by 67.13% to $15.4 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Total Non-Current Liabilities are $15.4 million (Q4 2025), $33.4 million (Q3 2025), and $21.8 million (Q2 2025).